Device Trial Radar · NCT04533503
Vis-Rx Post-Market Evaluation
Last checked: Nov 19, 2026Latest source record: Mar 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
257
Actual
Start
Feb 22, 2021
Primary completion
Jan 25, 2023
Study completion Jan 25, 2023
Sponsor
- Lead sponsor
- Gentuity, LLCNot on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 31, 2020
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Post-market clinical evaluation of the Gentuity High-Frequency Optical Coherence Tomography (HF-OCT) System and the Vis-Rx Micro-Imaging Catheter for use in Percutaneous Coronary Intervention (PCI) procedures.
Conditions
- Coronary Artery Disease
Interventions
HF-OCT Imaging with the Vis-Rx Micro-Imaging CatheterDevice
Intracoronary HF-OCT imaging of the target lesion(s) during the procedure.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical performanceTime frame: Immediately after the procedure
- Technical performanceTime frame: Up to 3 months following the procedure
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of South Florida
Tampa, Florida
Baptist Health Lexington
Lexington, Kentucky
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.